Celgene steps back from $1bn Sutro acquisition

Celgene steps back from $1bn Sutro acquisition. Instead opts for amended licensing deal with US biotech. ... Celgene has decided not to acquire US biotech Sutro Biopharma, opting instead for an amended licensing deal with the cancer immunotherapy

Teva to cut 7000 jobs, close 15 manufacturing sites

According to a Financial Times report, both AstraZeneca's Pascal Soriot and Jacqualyn Fouse, formerly chief operating officer at Celgene, have turned down the job.

Celgene, Agios get FDA OK for leukaemia drug Idhifa

Celgene, Agios get FDA OK for leukaemia drug Idhifa. Duo’s drug becomes first new AML therapy since Novartis' Rydapt. ... That kicked off in 2010 with a $130m upfront payment from Celgene to Agios.

Celgene joins PD-1 race via partnership with BeiGene

Celgene joins PD-1 race via partnership with BeiGene. The pharma giant will pay the Chinese firm up to $980m in milestone payments. ... Celgene has an earlier $450m deal with AstraZeneca on PD-L1 inhibitor durvalumab, just rolling out in its first markets

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 (Next 5)